Pharmaceuticals company Bajaj Healthcare announced Q3FY25 results Revenue: Rs 1,227.9 million compared to Rs 1,085.7 million during Q3FY24, change 13.1%. EBITDA: Rs 240.1 million compared to Rs 203.3 million during Q3FY24, change 18.1%. EBITDA margin: 19.6% for Q3FY25. PAT: Rs 117.2 million compared to Rs -219.6 million during Q3FY24, change 153.4%. PAT margin: 9.5% for Q3FY25. Anil Jain, Managing Director, said: “We are pleased to report yet another strong quarter of growth and profitability. Our PAT from continuing operations surged 171% YoY, driven by our relentless focus on operational excellence and cost efficiencies. At the same time, we remain committed to monetizing assets from discontinued operations, ensuring optimal capital allocation towards debt repayment and minimizing associated losses. Notably, our formulations segment saw a significant growth, with an impressive 58% YoY increase for the quarter. This rise in formulations revenue highlights the strength of our manufacturing expertise, as we continue to expand our portfolio and enhance our capabilities to meet market demand across key therapeutic areas. Our opium processing segment saw a 32% YoY growth and we remain optimistic about the long-term prospects of the alkaloid processing segment. Beyond financials, we reached significant milestones strengthening our market position. A key achievement was receiving approval from the Drug Controller General of India (DCGI) to manufacture both the API and formulation of Pimavanserin, solidifying our foothold in the central nervous system (CNS) segment. Pimavanserin, marketed globally as NUPLAZID®, has already gained significant traction in the US, and with Acadia Pharmaceuticals projecting combined net sales of over USD 1 billion in 2025 for NUPLAZID® and DAYBUE, we see a tremendous opportunity ahead. We are proud to expand our CDMO pipeline with a new contract for 15 APIs with UK/EU-based companies, reinforcing our global presence and expertise in cost-effective synthesis. This follows our earlier contract for 15 molecules this year. Additionally, the approval of our Gujarat API manufacturing site by the TGA, Australia, alongside USFDA and EU certifications, enables direct supplies to Australia and New Zealand, unlocking new global partnership opportunities. Looking ahead, we remain confident in our growth, driven by operational excellence, strategic partnerships, and innovation, as we work towards becoming a trusted global pharmaceutical partner.” Result PDF
Pharmaceuticals company Bajaj Healthcare announced Q2FY25 results Revenue from Operations: Rs 1,330.9 million compared to Rs 1,012.1 million, change 31.5% YoY. EBITDA: Rs 245.2 million compared to Rs 189.5 million, change 29.4% YoY. EBITDA Margin: 18.4% for Q2FY25. PAT: Rs 94.6 million compared to Rs -34.6 million. PAT Margin: 7.1% for Q2FY25. Anil Jain, Managing Director, said: “I am delighted to present the impressive results of our second quarter for FY25. Our revenue from operations surged by approximately 32% YoY led by robust performance across all segments this coupled with expansion in our margins resulted in a 90% year-onyear increase in our bottom line from our continuing operations. We continue to undertake all efforts to sell the assets from the discontinued operations and to use the proceeds for further debt repayment and minimize the losses from the discontinued operations. We have materially repaid our borrowings to the tune of Rs 1,500 million and this has further strengthened our financial position. Contribution from our API and Formulation segments rose, with both registering strong growth at 19% and 28%, respectively. The domestic demand has remained quite encouraging and has been a source of strength even as export markets are still largely wrestling sticky inflation and elevated freights. Another key highlight was the exceptional performance of our Opium Processing business, which grew multi-fold year-on-year. The segment has quickly become a meaningful growth driver for our overall business. We are focused on expanding capacity to meet increasing government requirements and sustain its high growth trajectory going forward. Our new development and supply agreement with a European partner for an Active Pharmaceutical Ingredient (API) underscores our commitment to maintaining the highest standards of quality, as evidenced by our adherence to Good Manufacturing Practices. This also presents us with a fascinating opportunity to showcase our development capabilities and further strengthen our CDMO business. It pleases me to report that we successfully completed an approximately Rs 2,050 million fund raise denoting the strong investor belief in our company’s abilities and our upcoming growth journey. We are now firmly on the path to maintaining profitability on an overall basis and look to carry forward this positive momentum from our recent performances.” Result PDF
Pharmaceuticals firm Bajaj Healthcare announced Q1FY23 Result : Revenue from Operations has marginally degrown by 7.32% from Rs.1,856.89 Mn in Q1 FY22 to Rs.1720.69 Mn in Q1 FY23 mainly due to contraction of Covid-19 led opportunities. EBITDA has degrown by 22.85% from Rs.334.98 Mn in Q1 FY22 to Rs.258.44 Mn in Q1 FY23. There was de-growth in EBIDTA Margins from 18.04% in Q1 FY22 to 15.02% in Q1 FY23 on a YoY basis. The degrowth in EBITDA margins was mainly on account of weakening of Indian Rupee, thereby leading to an increase in imported raw material cost. The EBITDA margins strengthened on a sequential quarter basis by 67bps. Net profit has decline by 37.46% from Rs.192.18 Mn in Q1 FY22 to Rs. 120.19 Mn in Q1 FY23. The Net Profit Margins were at 6.98% in Q1 FY23 from 10.35% in Q1 FY22 owing to a decline in EBITDA margins as explained above. Commenting on the Q1 FY23 results, Mr. Sajankumar Bajaj (Chairman) said: “We are pleased to inform all our stakeholders that the company has reported an overall stable financial performance in Q1 FY23 despite witnessing inflationary headwinds for the major part of the quarter. Despite declining contribution from Covid related products, The company was able to retain its revenue achieved in Q1FY22 on account of covid related demand and post an improvement in quarterly EBITDA margins on a sequential basis." Result PDF